Floatz logo

Bosutinib

Blasts More Than 5 Percent of Bone Marrow Nucleated Cells

M.D. Anderson Cancer CenterSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

33 Active assets in the Blasts More Than 5 Percent of Bone Marrow Nucleated Cells cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
University of Southern California
Phase 3BBB
Fludarabine
Fred Hutchinson Cancer Center
Phase 3BB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BB
TACROLIMUS
Fred Hutchinson Cancer Center
Phase 2BB
Idarubicine
Fred Hutchinson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Bosutinib is also rated in:

glioblastomaDormant
B
Indicative ·
59 / 100
View asset →
chronic myeloid leukemiaDormant
B
Indicative ·
57 / 100
View asset →
Lewy body dementiaDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →